



VIA E-MAIL

Ocugen  
Attention: Vijay Tammara, Ph.D.  
Senior Vice President, Global Regulatory and Quality  
263 Great Valley Parkway  
Malvern, Pennsylvania 19355

Re: Submission of Clinical Trial Information Pursuant to 42 U.S.C. 282(j)  
FDA Reference Number: CDER-2021-126  
NCT03785340

Dear Dr. Tammara:

On April 18, 2022, the Food and Drug Administration (FDA) sent your company a Notice of Noncompliance, dated April 15, 2022, regarding the requirements to submit clinical trial information to the ClinicalTrials.gov data bank. At this time, it appears that your company has addressed the issues raised in FDA's letter.

Sincerely,

*{See appended electronic signature page}*

Laurie Muldowney, M.D.  
Deputy Director  
Office of Scientific Investigations  
Office of Compliance  
Center for Drug Evaluation and Research  
U.S. Food and Drug Administration

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

LAURIE B MULDOWNEY  
08/01/2022 09:07:44 AM